248 related articles for article (PubMed ID: 3409330)
21. Potential to involve multiple effector cells with human recombinant interleukin-2 and antiganglioside monoclonal antibodies in a canine malignant melanoma immunotherapy model.
Helfand SC; Soergel SA; Donner RL; Gan J; Hank JA; Lindstrom MJ; Sondel PM
J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):188-97. PubMed ID: 7834118
[TBL] [Abstract][Full Text] [Related]
22. Cellular cytotoxicity mediated by isotype-switch variants of a monoclonal antibody to human neuroblastoma.
d'Uscio CH; Jungi TW; Blaser K
Br J Cancer; 1991 Sep; 64(3):445-50. PubMed ID: 1911183
[TBL] [Abstract][Full Text] [Related]
23. Canine lymphoma-associated antigens defined by murine monoclonal antibodies.
Steplewski Z; Jeglum KA; Rosales C; Weintraub N
Cancer Immunol Immunother; 1987; 24(3):197-201. PubMed ID: 3594482
[TBL] [Abstract][Full Text] [Related]
24. Human large granular lymphocytes express high affinity receptors for murine monoclonal antibodies of the IgG3 subclass.
Anasetti C; Martin PJ; Morishita Y; Badger CC; Bernstein ID; Hansen JA
J Immunol; 1987 May; 138(9):2979-81. PubMed ID: 2952730
[TBL] [Abstract][Full Text] [Related]
25. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages.
Mukherjee S; Lee SC; Casadevall A
Infect Immun; 1995 Feb; 63(2):573-9. PubMed ID: 7822024
[TBL] [Abstract][Full Text] [Related]
26. Analysis of a murine anti-ganglioside GD2 monoclonal antibody expressing both IgG2a and IgG3 isotypes: monoclonality, apoptosis triggering, and activation of cellular cytotoxicity on human melanoma cells.
Lin CC; Shen YC; Chuang CK; Liao SK
Adv Exp Med Biol; 2001; 491():419-29. PubMed ID: 14533812
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.
Drebin JA; Link VC; Greene MI
Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329
[TBL] [Abstract][Full Text] [Related]
28. Antibody-dependent, cell-mediated cytotoxicity by an anti-class II murine monoclonal antibody: effects of recombinant interleukin 2 on human effector cell lysis of human B-cell tumors.
Biddle WC; Pancook J; Goldrosen M; Han T; Foon KA; Vaickus L
Cancer Res; 1990 May; 50(10):2991-6. PubMed ID: 2334902
[TBL] [Abstract][Full Text] [Related]
29. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
[TBL] [Abstract][Full Text] [Related]
30. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.
Stein R; Qu Z; Chen S; Solis D; Hansen HJ; Goldenberg DM
Blood; 2006 Oct; 108(8):2736-44. PubMed ID: 16778139
[TBL] [Abstract][Full Text] [Related]
31. Isolation and characterization of anti-monosialoganglioside monoclonal antibody 19-9 class-switch variants.
Steplewski Z; Spira G; Blaszczyk M; Lubeck MD; Radbruch A; Illges H; Herlyn D; Rajewsky K; Scharff M
Proc Natl Acad Sci U S A; 1985 Dec; 82(24):8653-7. PubMed ID: 2934735
[TBL] [Abstract][Full Text] [Related]
32. Immunological tailoring of monoclonal antibodies for immunotherapy of pancreatic carcinoma.
Bosslet K; Döring N; Seemann G; Schulz G; Sedlacek HH
Int J Cancer Suppl; 1988; 2():85-8. PubMed ID: 3162450
[TBL] [Abstract][Full Text] [Related]
33. Hyperacute rejection by anti-Gal IgG1, IgG2a, and IgG2b is dependent on complement and Fc-gamma receptors.
Ding JW; Zhou T; Zeng H; Ma L; Verbeek JS; Yin D; Shen J; Chong AS
J Immunol; 2008 Jan; 180(1):261-8. PubMed ID: 18097027
[TBL] [Abstract][Full Text] [Related]
34. Activation of complement by monoclonal antibodies that target cell-associated β₂-microglobulin: implications for cancer immunotherapy.
Pokrass MJ; Liu MF; Lindorfer MA; Taylor RP
Mol Immunol; 2013 Dec; 56(4):549-60. PubMed ID: 23911412
[TBL] [Abstract][Full Text] [Related]
35. Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity.
Steplewski Z; Sun LK; Shearman CW; Ghrayeb J; Daddona P; Koprowski H
Proc Natl Acad Sci U S A; 1988 Jul; 85(13):4852-6. PubMed ID: 3387441
[TBL] [Abstract][Full Text] [Related]
36. Characterization of a series of isotype switch variants of a new CD20 monoclonal antibody.
Hooijberg E; Sein JJ; van den Berk PC; Hekman A
Hybridoma; 1996 Feb; 15(1):23-31. PubMed ID: 9064283
[TBL] [Abstract][Full Text] [Related]
37. Phenotypic characterization of canine lymphoma, using monoclonal antibodies and a microlymphocytotoxicity assay.
Ladiges WC; Keast M; Appelbaum F; Storb R
Am J Vet Res; 1988 Jun; 49(6):870-2. PubMed ID: 3400923
[TBL] [Abstract][Full Text] [Related]
38. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
39. Human monoclonal anti-D antibodies. II. The relationship between IgG subclass, Gm allotype and Fc mediated function.
Kumpel BM; Wiener E; Urbaniak SJ; Bradley BA
Br J Haematol; 1989 Mar; 71(3):415-20. PubMed ID: 2539182
[TBL] [Abstract][Full Text] [Related]
40. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
